| pubmed-article:1972347 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1972347 | lifeskim:mentions | umls-concept:C0032854 | lld:lifeskim |
| pubmed-article:1972347 | lifeskim:mentions | umls-concept:C0242957 | lld:lifeskim |
| pubmed-article:1972347 | lifeskim:mentions | umls-concept:C0677886 | lld:lifeskim |
| pubmed-article:1972347 | lifeskim:mentions | umls-concept:C1514559 | lld:lifeskim |
| pubmed-article:1972347 | lifeskim:mentions | umls-concept:C0038952 | lld:lifeskim |
| pubmed-article:1972347 | lifeskim:mentions | umls-concept:C0332281 | lld:lifeskim |
| pubmed-article:1972347 | lifeskim:mentions | umls-concept:C1561558 | lld:lifeskim |
| pubmed-article:1972347 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:1972347 | pubmed:issue | 13 | lld:pubmed |
| pubmed-article:1972347 | pubmed:dateCreated | 1990-7-23 | lld:pubmed |
| pubmed-article:1972347 | pubmed:abstractText | Previous studies have suggested that overexpression of HER-2/neu oncogene occurs in 15-40% of breast cancers and that overexpression is associated with poor prognosis. In the present report, we have used an immunohistochemical technique involving a monoclonal antibody specifically reactive with the external domain of HER-2/neu to study expression of HER-2/neu in frozen sections of normal ovary and advanced epithelial ovarian cancer. The intensity of staining for HER-2neu was always moderate or less (0-2+) in normal ovarian epithelium. Among 73 ovarian cancers, 50 (68%) had staining similar to that for normal ovarian epithelium (0-2+) while 23 (32%) stained heavily (3+). Survival of the 23 patients with high HER-2/neu expression (median, 15.7 months) was significantly worse (P = 0.001) than that of the 50 patients (median, 32.8 months) with normal HER-2/neu expression. In addition, patients whose tumors had high HER-2/neu expression were significantly less likely to have a complete response to primary therapy (P less than 0.05) or have a negative second-look laparotomy when serum CA 125 levels were normal preoperatively (P less than 0.05). These findings suggest that HER-2/neu deserves further evaluation as a prognostic marker in epithelial ovarian cancer. | lld:pubmed |
| pubmed-article:1972347 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1972347 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1972347 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1972347 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1972347 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1972347 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1972347 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1972347 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:1972347 | pubmed:issn | 0008-5472 | lld:pubmed |
| pubmed-article:1972347 | pubmed:author | pubmed-author:MarksPP | lld:pubmed |
| pubmed-article:1972347 | pubmed:author | pubmed-author:WhitakerRR | lld:pubmed |
| pubmed-article:1972347 | pubmed:author | pubmed-author:KamelAA | lld:pubmed |
| pubmed-article:1972347 | pubmed:author | pubmed-author:DodgeRR | lld:pubmed |
| pubmed-article:1972347 | pubmed:author | pubmed-author:TORIIHH | lld:pubmed |
| pubmed-article:1972347 | pubmed:author | pubmed-author:Clarke-Pearso... | lld:pubmed |
| pubmed-article:1972347 | pubmed:author | pubmed-author:BerchuckAA | lld:pubmed |
| pubmed-article:1972347 | pubmed:author | pubmed-author:KinneyRR | lld:pubmed |
| pubmed-article:1972347 | pubmed:author | pubmed-author:HoT CTC | lld:pubmed |
| pubmed-article:1972347 | pubmed:author | pubmed-author:KernsBB | lld:pubmed |
| pubmed-article:1972347 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1972347 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:1972347 | pubmed:volume | 50 | lld:pubmed |
| pubmed-article:1972347 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1972347 | pubmed:authorsComplete | N | lld:pubmed |
| pubmed-article:1972347 | pubmed:pagination | 4087-91 | lld:pubmed |
| pubmed-article:1972347 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
| pubmed-article:1972347 | pubmed:meshHeading | pubmed-meshheading:1972347-... | lld:pubmed |
| pubmed-article:1972347 | pubmed:meshHeading | pubmed-meshheading:1972347-... | lld:pubmed |
| pubmed-article:1972347 | pubmed:meshHeading | pubmed-meshheading:1972347-... | lld:pubmed |
| pubmed-article:1972347 | pubmed:meshHeading | pubmed-meshheading:1972347-... | lld:pubmed |
| pubmed-article:1972347 | pubmed:meshHeading | pubmed-meshheading:1972347-... | lld:pubmed |
| pubmed-article:1972347 | pubmed:meshHeading | pubmed-meshheading:1972347-... | lld:pubmed |
| pubmed-article:1972347 | pubmed:meshHeading | pubmed-meshheading:1972347-... | lld:pubmed |
| pubmed-article:1972347 | pubmed:meshHeading | pubmed-meshheading:1972347-... | lld:pubmed |
| pubmed-article:1972347 | pubmed:meshHeading | pubmed-meshheading:1972347-... | lld:pubmed |
| pubmed-article:1972347 | pubmed:year | 1990 | lld:pubmed |
| pubmed-article:1972347 | pubmed:articleTitle | Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. | lld:pubmed |
| pubmed-article:1972347 | pubmed:affiliation | Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina 27710. | lld:pubmed |
| pubmed-article:1972347 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1972347 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1972347 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1972347 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1972347 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1972347 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1972347 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1972347 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1972347 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1972347 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1972347 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1972347 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1972347 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1972347 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1972347 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1972347 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1972347 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1972347 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1972347 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1972347 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1972347 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1972347 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1972347 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1972347 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1972347 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1972347 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1972347 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1972347 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1972347 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1972347 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1972347 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1972347 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1972347 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1972347 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1972347 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1972347 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1972347 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1972347 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1972347 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1972347 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1972347 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1972347 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1972347 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1972347 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1972347 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1972347 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1972347 | lld:pubmed |
